**Texas Files Lawsuit Against Tylenol Over Unsubstantiated Autism Claims**
:max_bytes(150000):strip_icc():format(jpeg)/Tylenol-packages-102825-1163fd303353461b9c6b8acf9f61cfb8.jpg)
In a controversial move, Texas Attorney General Ken Paxton has launched a legal battle against the makers of Tylenol, alleging that they concealed information regarding the risks the medication poses to pregnant women and young children. The lawsuit, targeting manufacturer Kenvue and former parent company Johnson & Johnson, accuses the companies of promoting Tylenol to expectant mothers while allegedly being aware of its link to autism—a claim that has sparked intense debate among medical experts.
Paxton’s decision to take legal action was driven by his assertion that the manufacturers knew about the dangers associated with acetaminophen, Tylenol’s active ingredient, yet continued to market the drug as a safe option for pregnant women. The lawsuit alleges that this conduct violated the Texas Deceptive Trade Practices-Consumer Protection Act. In a statement released on October 28, Paxton condemned the pharmaceutical industry for prioritising profits over public safety, accusing them of jeopardising the health of millions for financial gain.
The controversy surrounding Tylenol and autism was further fuelled by President Donald Trump’s bold statements during a press conference alongside Health and Human Services Secretary Robert F. Kennedy Jr. and Dr Mehmet Oz from the Centers for Medicare and Medicaid Services. Trump’s unsubstantiated claims that Tylenol usage during pregnancy leads to autism have been met with scepticism from the medical community, with experts emphasising the long history of safe use of the drug since the 1960s.
Contrary to the sensational assertions, medical professionals have reiterated that the association between acetaminophen and autism remains inconclusive, citing a study published in Environmental Health that suggests a potential link between prenatal exposure to the drug and neurodevelopmental disorders without establishing direct causation. Dr Karam Radwan from the UChicago Medicine Neurodevelopmental Clinic highlighted that underlying health issues requiring prolonged Tylenol use during pregnancy might play a significant role in any observed connections.
Kenvue, the primary target of the lawsuit, has vehemently denied the allegations, stressing their commitment to the health and well-being of their consumers. They emphasised the importance of acetaminophen as a safe option for pain relief in pregnant women, underscoring the risks associated with untreated conditions such as fever. Similarly, a spokesperson for Johnson & Johnson clarified that the company had divested its consumer health division, with all rights and obligations related to over-the-counter products like Tylenol now belonging to Kenvue.
As the legal battle intensifies, Kenvue and Johnson & Johnson are gearing up to defend themselves against the allegations raised by the Texas Attorney General. The outcome of this lawsuit could have far-reaching implications for the pharmaceutical industry and the regulation of medication marketing practices. Amidst the ongoing controversy, the safety and efficacy of acetaminophen, a widely used pain reliever, remain under scrutiny, underscoring the importance of transparency and accountability in the healthcare sector.